Poll suggests oncologists already using GSK melanoma drugs off-label

Share this article:

A survey conducted by BioTrends Research Group found that of the U.S. oncologists polled, that  25% had prescribed GSK's BRAF-inhibitor Tafinlar for malignant melanoma, compared to 15% who said they prescribed GSK's MEK inhibitor, Mekinist. This study, part of the “LaunchTrends Tafinlar/Mekinist” report series, suggests the inability to differentiate between Taflinar and Mekinist is the most significant constraint for oncologists prescribing these new launch drugs. The report also alleges that oncologists may be using the two together in a non-FDA approved combination therapy. Another finding was that nearly half of oncologists surveyed are willing to prescribe both Taflinar and Mekinist as monotherapies. More oncologists also cited Tafinlar as the first-line BRAF-mutated unresectable/metastatic malignant melanoma treatment to be prescribed, Mekinist was cited as the most likely to prescribe in patients with the BRAF V600k Mutation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.